July 23, 2007 - CMS Inc. has completed internal and external validation testing for its new Monaco IMRT planning system, which has gained the European CE mark, and is now applying to the Food and Drug Administration for 510(k) clearance to distribute Monaco in the U.S. market.
With Monaco, CMS will offer new approaches designed to improve the following: repetitive trial-and-error methods for determining the optimal plan; multiple variables to manage the planning process including patient data, contours, and the optimization itself; a generally non-intuitive IMRT planning process; a lack of control over the “black box” optimization process.
For more information: www.cmsrtp.com